The syndrome and time course come before the antibody label
Heidelberg describes autoimmune encephalitis as a rare group of disorders associated with different neuronal autoantibodies, but notes that antibodies are not detected in every case. Charité treats anti-NMDA-receptor, LGI1/CASPR2 and other surface-antibody encephalitides as well as paraneoplastic syndromes. A specialist review should ask whether the clinical course is compatible with autoimmune brain inflammation and whether infectious, metabolic, toxic, vascular, epileptic or primary psychiatric explanations have been adequately excluded.
- Rapidly developing memory or cognitive decline
- New epileptic seizures or status epilepticus
- Behavioral or psychiatric change
- Movement disorders or abnormal involuntary movements
- Altered consciousness or sleep-wake disturbance
- Autonomic instability or other neurological deficits
Serum and CSF antibody testing should be interpreted together
The relevant antibody depends on the syndrome. Heidelberg distinguishes antibodies against neuronal cell-surface structures from antibodies against intracellular antigens, which can have different mechanisms, treatment responses and cancer associations. CSF can be important both for autoimmune-antibody testing and for excluding infectious encephalitis.
MRI and EEG contribute different evidence
Heidelberg includes brain imaging and EEG in the diagnostic pathway. MRI can identify limbic or other inflammatory patterns but may be nondiagnostic in some patients. EEG can help identify seizures, non-convulsive status or encephalopathic abnormalities. The diagnosis should therefore integrate several evidence streams rather than rely on one normal or abnormal test.
Tumor screening can be central in paraneoplastic syndromes
Heidelberg notes that autoimmune encephalitis associated with some intracellular neuronal antibodies is very strongly linked to malignancy. Charité has a dedicated encephalitis and paraneoplasia program. The extent and repetition of tumor screening should depend on the antibody, age, sex, clinical syndrome and prior findings rather than using one identical screening protocol for everyone.
Acute immunotherapy is usually hospital-based
Heidelberg describes stepwise treatment using high-dose intravenous corticosteroids, intravenous immunoglobulins and blood-wash/apheresis procedures. The exact sequence depends on disease severity, suspected mechanism, response and contraindications. Severe encephalitis can also require seizure treatment, intensive-care monitoring and management of autonomic or behavioral complications.
Long-term immunotherapy is individualized
For selected patients, Heidelberg describes longer-term immunosuppressive treatment to reduce recurrence. The need for maintenance therapy varies substantially by antibody syndrome, relapse history, treatment response and cancer status. A generic 'autoimmune encephalitis protocol' is therefore less useful than an antibody- and phenotype-specific plan.
Treating an associated tumor is part of neurological management
When a relevant malignancy is identified, Heidelberg emphasizes prompt tumor treatment because control of the cancer can influence neurological recovery. This can require coordination across neurology, oncology, surgery and radiation oncology rather than treating the encephalitis as an isolated neurological problem.
Second opinion is most useful after acute stabilization
Charité and Freiburg provide specialist follow-up or second-opinion pathways for autoimmune encephalitis and difficult neuroimmunological cases. International review is most appropriate when the patient is medically stable and the goal is diagnostic confirmation, antibody interpretation, relapse-prevention planning, tumor-surveillance strategy or rehabilitation/follow-up coordination.
What to send for a German autoimmune-encephalitis review
A useful record package should reconstruct the timeline from first symptoms through acute treatment and recovery.
- Neurology, ICU and discharge reports
- Serum and CSF neuronal-antibody results with laboratory details
- Complete CSF results including infectious testing
- Brain MRI in original DICOM format when requested
- EEG reports and prolonged EEG findings if performed
- Seizure history and anti-seizure medication
- Tumor-screening imaging and pathology if any malignancy was found
- Steroid, IVIG, plasma-exchange/immunoadsorption and other immunotherapy history
- Current cognitive, psychiatric, movement and functional status
- A specific question: confirm diagnosis, interpret antibodies, plan maintenance therapy, review cancer surveillance or coordinate recovery
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Autoimmune encephalitis – diagnosis and treatment — Heidelberg University Hospital ↗
- Neuroimmunology outpatient clinic — Heidelberg University Hospital ↗
- Encephalitis & paraneoplastic neurological disease — Charité – Universitätsmedizin Berlin ↗
- Inflammatory CNS diseases outpatient clinic — University Medical Center Freiburg ↗